Kenvue (KVUE) Q4 2025 earnings review
Merger with Kimberly-Clark Announced; Organic Growth Returns
Kenvue is being acquired by Kimberly-Clark (expected close H2 2026), overshadowing a pivotal quarter where the company finally arrested its sales slide. After three consecutive quarters of contraction, Organic Sales returned to growth (+1.2%), driven by a rebound in Skin Health & Beauty and strong Essential Health performance. However, the quality of growth remains mixed: price (+2.3%) is doing the heavy lifting while volumes continue to decline (-1.1%). Profitability improved, with Adjusted Operating Margin expanding 70 bps to 19.9% due to supply chain efficiencies.
🐂 Bull Case
The turnaround strategy is showing results. Organic sales flipped from -4.4% in Q3 to +1.2% in Q4, with Skin Health & Beauty—a long-time laggard—posting +1.5% organic growth driven by innovation and execution outside North America.
Despite inflationary headwinds and tariff costs, Adjusted Gross Margin expanded 10 bps and Adjusted Operating Margin expanded 70 bps (to 19.9%), validating the 'Our Vue Forward' productivity initiatives.
🐻 Bear Case
Consumer demand remains fragile. While revenue grew, it was entirely price-driven (+2.3%). Volumes declined 1.1% globally, with Self Care volumes dropping a concerning 3.1%.
The largest segment, Self Care, contracted 1.2% organically. Low seasonal incidences (flu/cold) in the U.S. and trade inventory reductions continue to weigh on the unit.
⚖️ Verdict: ⚪
Neutral. The operational turnaround is visibly taking shape with a return to top-line growth and solid margin management. However, the investment thesis is now effectively an arbitrage play on the Kimberly-Clark merger closing, rendering standalone fundamental analysis secondary.
Key Themes
Acquisition by Kimberly-Clark
Kenvue entered a definitive merger agreement with Kimberly-Clark on Nov 2, 2025. Shareholders have approved the deal, and the Hart-Scott-Rodino waiting period expired Feb 4, 2026. The deal is expected to close in H2 2026. Consequently, Kenvue suspended all forward guidance and cancelled the earnings call.
Turnaround in Skin Health & Beauty
Reversing. After multiple quarters of decline (reaching -3.7% in Q2), Skin Health & Beauty posted +1.5% organic growth. Innovations and commercial execution drove growth in every region outside North America. This validates the management changes and strategic review initiated earlier in the year.
Self Care Volumes Under Pressure
Decelerating. Self Care organic sales fell 1.2%, driven by a sharp 3.1% decline in volume. Management cited 'subdued seasonal incidences' in the U.S. and trade inventory reductions. While Tylenol share trends improved in December, the segment remains a drag on the total company portfolio.
Essential Health Momentum
Accelerating. Essential Health was the standout performer with +6.1% reported and +4.2% organic growth. Crucially, it was the only segment with positive volume growth (+1.3%). Growth was broad-based across Asia Pacific, LatAm, and EMEA, with sequential improvement in North America.
Tariff and Inflation Headwinds
While margins expanded, management explicitly noted impacts from 'inflationary, tariff, and transactional foreign exchange headwinds.' The effective tax rate also spiked to 22.7% (vs 15.3% prior year) due to fewer discrete tax benefits, weighing on GAAP net income.
Other KPIs
Stable. Expanded 10 basis points YoY. Productivity gains from supply chain optimization successfully offset inflation and tariff costs.
Accelerating. Up significantly from $1.3 billion in the prior year, driven by improvements in working capital. Operating cash flow reached $2.2 billion.
Total debt stands at $8.5 billion, essentially flat YoY ($8.6B). Cash position is $1.1 billion. Balance sheet remains stable ahead of the acquisition.
Guidance
Due to the pending transaction with Kimberly-Clark, the Company will not be providing forward-looking guidance.
Key Questions
Closing Timeline Risks
With the HSR waiting period expired, what specific foreign regulatory approvals remain outstanding for the Kimberly-Clark merger, and are there any jurisdictions posing significant remedy risks?
Self Care Structural vs. Seasonal
Self Care volume declined 3.1%. Beyond the weak flu season, are you seeing any structural shifts in consumer preference toward private label or competitor brands in the pain category?
Employee Retention
With the merger expected to close in H2 2026, have you observed any increase in key talent attrition, and what retention programs are in place to ensure operational stability during the transition?